Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAGER: Piperacillin/tazobactam vs ampicillin + gentamicin for community-acquired infection
2026-526131-20-00Phase 4Authorised
- Sponsor
- Capital Region of Denmark
- Start
- Aug 2026
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in urosepsis, urinary tract infection (UTI), cystitis and 4 more comparing Piperacillin/tazobactam arm with Ampicillin + gentamicin arm (2 arms). Primary endpoints: 30-day all-cause mortality and 30-day acute kidney injury. Planned start Aug 2026; status: authorised.
02
Drugs
piperacillin + tazobactamampicillin + gentamicin
03
Conditions
urosepsisurinary tract infection (UTI)cystitispyelonephritispneumonia
Beyond the preview
Go deeper on 2026-526131-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526131-20-00.